Comerica Bank Fate Therapeutics Inc Transaction History

Comerica Bank

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$3.54 - $8.35 $1,239 - $2,922	350 Added 66.16%	879 $6,000
Q4 2023 Feb 14, 2024	BUY	$1.65 - $3.94 $872 - $2,084	529 New	529 $1,000
Q4 2022 Jan 26, 2023	BUY	$9.86 - $23.83 $101,755 - $245,925	10,320 Added 8.36%	133,760 $0
Q3 2022 Oct 28, 2022	SELL	$21.04 - $36.06 $734,085 - $1.26 Million	-34,890 Reduced 22.04%	123,440 $2.33 Million
Q2 2022 Aug 02, 2022	BUY	$17.78 - $42.39 $902,850 - $2.15 Million	50,779 Added 47.21%	158,330 $5.15 Million
Q1 2022 Apr 27, 2022	BUY	$29.67 - $60.28 $3.19 Million - $6.48 Million	107,551 New	107,551 $4.17 Million
Q1 2021 Apr 28, 2021	SELL	$72.16 - $117.4 $170,514 - $277,416	-2,363 Closed	0 $0
Q4 2020 Jan 28, 2021	BUY	$38.09 - $100.95 $90,006 - $238,544	2,363 New	2,363 $214,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $143M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Comerica Bank, based on Form 13F filings with the SEC.

Stay updated on Comerica Bank with notifications on news.